ABSTRACT: Progesterone and estrogens play key roles in regulating various physiological phenomena related to normal growth, development, and reproduction of domestic animals. This review focuses on the mechanisms by which progesterone and estrogens regulate the reproductive processes in these animals. The majority of research on the actions of progesterone and estrogens on the reproductive systems of cattle, sheep, and pigs has been genomic in nature and represents attempts to better understand how these steroids regulate gene expression. Results of recent research suggest that progesterone and estrogens can alter target cell responses nongenomically via membrane receptors.
INTRODUCTION
Steroid hormones regulate a host of physiological processes in domestic animals, but chief among those that affect productivity are mammary gland development, reproductive successes, and hypothalamus-hypophyseal functions. In domestic animals, steroids have been used primarily to promote growth, synchronize estrus, and maintain pregnancy. Since the discovery of nuclear steroid receptors and their roles as transcription factors, it has generally been assumed that all steroids act directly to regulate gene expression, a "genomic" action. However, in recent years, experimental evidence has been presented indicating that steroids can provoke responses in target cells independent of gene transcription, a "nongenomic" action by the steroid. For purposes of classification, a nongenomic steroid effect is one detectable within seconds to minutes after exposure to 1 
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The characteristics of membrane receptors for progesterone and estrogen in various cell types are described and the intracellular signal pathways defined. Estrogens acting via membrane receptors can suppress LH secretion by gonadotropes and stimulate rapid increases in uterine blood flow. Progesterone acting via a membrane receptor has been shown to inhibit binding of oxytocin to oxytocin receptors in isolated endometrial plasma membranes and stimulate capacitation of spermatozoa. Results of research suggest that progesterone and estrogens can act nongenomically to alter target cell responses in domestic animals. The biological implications of this mode of action in these animals are discussed.
the steroid. By contrast, genomic responses to steroids generally require hours before being detectable.
From the standpoint of steroids and domestic animals, most interest has focused on the roles of progesterone (P 4 ) and estrogen because of their effects on the reproductive tract and anterior pituitary gonadotropin secretion. Thus, for comparative purposes this review provides a brief overview of the genomic actions of estrogen and P 4 in domestic animals. However, major emphasis is placed on describing the current state of knowledge regarding the nongenomic action of estrogen and P 4 in domestic animals with reference to relevant research in other species. scription activation subdomains or functions, referred to as AF (Tsai and O'Malley, 1994; Edwards, 2005) . The AF-1 in the N-terminal domain and ligand-dependent AF-2 present within the LBD are essential for gene transcription. Receptors to which estrogen or P 4 are bound become activated by their disassociation from protein chaperone molecules, dimerization, and subsequent binding of the steroid-receptor complex to a steroid response element usually localized in the promoter region of the gene (Tsai and O'Malley, 1994; Kumar and Thompson, 2003) . Transcription of genes by the steroid-receptor complex may be altered by recruitment of protein coactivators or corepressors to AF-1, AF-2, or both (McKenna et al., 1999; Smith and O'Malley, 2004) . The resulting coactivators or corepressors in association with the ligand-bound receptor ultimately facilitate the assembly of the RNA polymerase II complex that promotes gene transcription.
Two forms of the nuclear estrogen receptor (ER) are found in mammalian species. These 2 receptor subtypes are products of different genes and are designated ER α (ERα) and ERβ. Both monomeric forms of each receptor subtype are approximately 60 kDa, and both subtypes bind estradiol-17β with high affinity but differ in DNAbinding affinity. Estrogen receptor α and ERβ can be coexpressed in some target tissues but they also exhibit different tissue or cell expression patterns (Hall and McDonnell, 1999; Heldring et al., 2007) .
The PR also exists as 2 isoforms, designated as PR-A and PR-B (Edwards, 2005) . The 2 isoforms of PR arise from a single gene as a result of alternating promoter start sites that give rise to 2 different PR mRNA. Progesterone receptor-A and PR-B have identical homologies of the LBD, DNA-binding domain, and AF-1 of the N-terminal domain; however, PR-A differs from the fulllength PR-B by truncation of the most N-terminal 164 AA. The 2 isoforms of PR differ in their functional activities. Both isoforms are coexpressed in most target tissues, but the ratio of the 2 forms of PR can vary depending on cell type or physiological state. An AF-3 domain within the most N-terminal 164 AA of PR-B promotes a stronger transcriptional activity by PR-B (Li and O'Malley, 2003) . It has been reported that PR-A can act as a transrepressor of PR-B and perhaps other steroid receptors such as ER (Edwards, 2005) . In PR-A and PR-B knockout mice, PR-A has been found to play a major role in mediating the actions of P 4 in the uterus and ovary, whereas PR-B is more important in mammary gland development (Mulac-Jericevic et al., 2000 , 2003 .
CHANGES IN UTERINE AND HYPOPHYSEAL NUCLEAR ER AND PR DURING VARIOUS REPRODUCTIVE STATES
Early reports documented the presence of nuclear estrogen and PR in the oviduct, uterus, and pituitary of laboratory animals. These studies served as the impetus to examine the concentrations of nuclear estrogen and PR in these target tissues in domestic animals. Uterine (endometrial) concentrations of nuclear estrogen and PR, as measured by radioreceptor assays, were found to increase during proestrus, attain maximal levels at estrus and metestrus, and then gradually decrease during the midluteal phase of the bovine and ovine estrous cycle (Senior, 1975; Koligian and Stormshak, 1977a; Miller et al., 1977; Zelinski et al., 1982; Robinson et al., 2001) . Similarly, in the ewe, steady-state concentrations of endometrial ER mRNA and PR mRNA, found predominantly in the luminal and glandular epithelium, were maximal at estrus to metestrus, markedly reduced during the midluteal phase of the cycle, and then increased late (d 11 to 15) in the luteal phase . In pregnant ewes, changes in endometrial ER and PR mRNA, as well as concentrations of respective receptors, were similar to those of the nonpregnant ewe at comparable stages after estrus, except concentrations of mRNA and protein in the luminal and glandular epithelium remained as at the midluteal phase and were very low or absent between d 13 to 25 of gestation .
By simply examining the relationship between uterine concentrations of ER and PR and systemic levels of estrogen and P 4 , one might deduce that estrogen upregulates both ER and PR. Indeed, this aspect of estrogen action in the endometrium was confirmed by using ovariectomized ewes treated with estrogen or P 4 alone or in combination (Koligian and Stormshak, 1977b) .
Comparatively few studies have been conducted to quantify estrogen and PR in the anterior pituitary or hypothalamus of domestic animals. Early research established the presence of androgen and ER in the hypothalamus and anterior pituitary of the ram and ewe (Pelletier and Caraty, 1981; Glass et al., 1984) . Subsequent research revealed that estrogen and androgen receptors were present in various morphological nuclei throughout the ovine hypothalamus. However, those cells containing the greatest concentrations of ER in the hypothalamus of the ewe were located in the preoptic area, ventromedial nucleus, and arcuate nucleus (Herbison et al., 1993; Lehman et al., 1993) . Similarly, these same sites in the hypothalamus of the ram were found to be richly endowed with androgen receptors (Herbison, 1995) . Alexander et al. (1993) examined quantities of ER in the hypothalamus, medial amygdala, and anterior pituitary of high and low sexually performing rams. The total number of ER in the anterior pituitary was nearly 100-fold greater than the number present in hypothalamic regions. The proportion of total ER in the preoptic area of the hypothalamus that was bound by estradiol-17β was significantly greater in high-performing than in low-performing rams. In contrast, the proportion of ER that was occupied with estradiol-17β in the anterior pituitary of high-performing rams tended to be less than that in low-performing rams. These differences in ER did not appear to affect secretion of LH during sexual behavior testing because high and low sexually performing rams had similar LH profiles relative to systemic basal concentrations, number of secretory pulses, and pulse amplitude of the gonadotropin.
During the estrous cycle of the cow, quantities of estrogen and GnRH receptors in the anterior pituitary are markedly increased prior to the preovulatory surge of LH (Nett et al., 1987) . Estrogen of follicular origin apparently causes upregulation of the ER and GnRH receptors (Turzillo and Nett, 1999) . Significant increases in estradiol receptors in the hypothalamus and anterior pituitary of ewes on d 22 postpartum were found to immediately precede the onset of ovarian cyclicity (Wise et al., 1986) . In postpartum cows, receptors for both GnRH and estradiol in the anterior pituitary are lowest immediately after parturition, then increase to maximal concentrations by 2 wk postpartum (Nett et al., 1988) . Pituitary content of LH in the cow is low following parturition and increases significantly through d 30 postpartum. Exposure of the anterior pituitary to the high systemic concentrations of placental estrogen that are prevalent during the late stage of gestation may be responsible for downregulating estrogen and GnRH receptors and for synthesis of LH. Indeed, chronic treatment of ovariectomized ewes with estradiol for 3 wk caused a reduction in mRNA for the LH α and β subunits in the anterior pituitary (Nilson et al., 1983) . Collectively, these reports suggest that the estradiol exhibits a paradoxical effect on LH synthesis, with low physiological levels stimulating and chronic levels inhibiting the synthesis of this gonadotropin. On the other hand, estradiol, whether chronically administered to ovariectomized ewes or added to primary ovine pituitary cell cultures at physiological concentrations, significantly increased the synthesis and secretion of prolactin Vician et al., 1979) . Progesterone suppressed the estradiol-induced increase in preprolactin mRNA production and prolactin synthesis.
P 4 , ESTRADIOL, AND UTERINE OXYTOCIN RECEPTORS
Binding of oxytocin (OT) to its receptor in the uterine endometrium of the nonpregnant ruminant stimulates pulsatile secretion of PGF 2α , which causes regression of the corpus luteum (McCracken et al., 1999) . Because the uterus is a target organ for P 4 and estrogen, considerable research has been conducted to elucidate the role of these ovarian steroids in regulating the uterine expression of the OT receptor (OTR). In the ewe and cow, concentrations of OTR localized in the uterine luminal and superficial glandular epithelium of the endometrium are maximal at estrus, become virtually absent or nondetectable during the midluteal phase of the estrous cycle, and on d 14 (ewe) or 15 (cow) reappear in these cells and continue to increase in number until onset of behavioral estrus (Sheldrick and Flint, 1985; Fuchs et al., 1990; Jenner et al., 1991; Wallace et al., 1991; Robinson et al., 2001 ). In the ewe, the increase in endometrial concentrations of OTR coincides with the rise in ovarian venous estradiol-17β and the reduction in systemic concentrations of P 4 as a consequence of luteolysis (Sheldrick and Flint, 1985) . On the basis of these observations, it would seem logical to assume that estrogen upregulates and P 4 downregulates the uterine OTR. Such effects of estrogen and P 4 are consistent with reported changes in expression of receptors for these steroids in uterine tissues during the course of the estrous cycle. Luminal and superficial glandular epithelial cells of the ovine uterus are endowed with ER mRNA and protein on d 14 and 15, but there is an absence of PR mRNA and nuclear receptor from d 6 to 13 of the cycle . Thus, the appearance of OTR in the luminal epithelium in the absence of functional nuclear PR (nPR) may be due to the unimpeded action of estradiol being produced by the developing ovarian follicle(s).
Experimental evidence also indicates that exogenous estradiol can upregulate uterine concentrations of OTR. Treatment of ovariectomized ewes with P 4 (5 to 12 d) followed by 2 d of estradiol treatment caused an increase in the uterine endometrium OTR as compared with treatments with P 4 only (Vallet et al., 1990) . Further, exposure of bovine endometrial explants to estradiol stimulated an increase in OTR compared with levels of receptor present in control explants (Leung and Wathes, 2000) . Whereas the reporter region of the bovine OTR gene contains at least 3 estrogen response element (ERE) half-sites, there is no firm evidence that the ligand-bound ER binds directly to these sites to stimulate OTR expression (Telgmann et al., 2003) . Similarly, the promoter region of the ovine OTR gene contains neither full ERE or ERE half-sites (Fleming et al., 2006) . Deletion and mutation analysis of the promoter region of the ovine OTR revealed that stimulation of the gene by estradiol is dependent on a guanine-cytosine-rich SP1 binding site at −104 and −64 bp.
Overall, experimental evidence favors a conclusion that estrogen upregulates and P 4 downregulates uterine OTR. However, the intracellular dynamics of OTR expression in uterine target cells, as affected by exposure to estrogen and P 4 during the estrous cycle, may be more complex than presently envisioned.
Pregnancy recognition in the ruminant encompasses the production of interferon-τ (IFN-τ) by the developing conceptus, which inhibits development of the endometrial luteolytic mechanism and pulsatile release of PGF 2α (Bazer, 1992) . It has been shown experimentally that IFN-τ acts to prevent increases in endometrial ER mRNA and protein, with a consequent reduction in OTR and a suppression in the uterine release of PGF 2α Spencer and Bazer, 1996) . It has been proposed that the antiluteolytic effects of IFN-τ are mediated by the direct inhibition of ERα gene transcription, thereby preventing ligand-bound ER from stimulating OTR gene transcription (Fleming et al., 2006) .
UTERINE BLOOD FLOW DURING THE ESTROUS CYCLE
The roles of estrogens and P 4 in regulating uterine blood flow have been studied extensively for more than 30 yr. Uterine blood flow in the cow, ewe, and sow varies during the estrous cycle in synchrony with the changing ratios of estrogen to P 4 concentration in systemic blood (Greiss and Anderson, 1969; Ford and Christenson, 1979; . Uterine blood flow is markedly greater immediately prior to and during the onset of estrus, followed by a reduced flow during the luteal phase of the cycle (Ford, 1982) . Thus, P 4 promotes vasoconstriction, which may contribute to the reduced uterine blood flow. In unilaterally ovulating ewes and cows, removal of segments of the uterine artery ipsilateral to the ovary bearing the corpus luteum (CL) respond in vitro to periarterial nerve stimulation with greater contractility than arterial segments on the contralateral side (Ford et al., 1976) . These data were interpreted to suggest that the uterine artery supplying the horn ipsilateral to the ovary bearing the CL were exposed to a greater local concentration of P 4 than the contralateral uterine artery. Indeed, it was subsequently demonstrated that in the cow (Pope et al., 1982) and ewe (Weems et al., 1989) uterine tissues on the side ipsilateral to the ovary with the CL contain a greater concentration of P 4 than tissues on the contralateral side. This difference in tissue concentration of P 4 between the ipsilateral and contralateral sides of the uterus is attributed to lymphatics draining the ovary (Lindner et al., 1964) , which are in close association with the uteroovarian vasculature (Morris and Sass, 1966 ).
The precise mechanism by which P 4 promotes vasoconstriction of uterine arteries is unknown. However, either directly or indirectly, P 4 causes an increase in the concentration of uterine arterial smooth muscle α 1 -adrenergic receptors (Ford et al., 1984) . Activation of these adrenergic receptors by norepinephrine emanating from periarterial sympathetic nerves results in vasoconstriction of the uterine vascular bed (Greiss and Pick, 1964) .
Exposure of the uterine artery to estrogen results in a rapid increase in blood flow. Injection of estrogen directly into the uterine arteries of ovariectomized ewes increases blood flow within 30 min (Killam et al., 1973) . Similarly, in ovariectomized cows an increase in uterine blood flow occurred within 20 to 40 min after injection of 1 g of estradiol-17β into the uterine artery (Ford and Reynolds, 1983) . The speed with which this uterine response to estrogen occurs suggests that the steroid is acting nongenomically in the vasculature.
Estrogen synthesized by porcine and bovine conceptuses is believed to act locally to promote transient increases in blood flow to the gravid uterine horn during early gestation. In sows, uterine venous blood and uterine flushings contained increased quantities of estrogen coincident with a transient increase in uterine blood flow on d 13 of gestation . Similarly, in cows a transient increase in blood flow to the gravid horn occurs on d 14 to 18, and during this time the venous blood draining this horn contains increased concentrations of estradiol-17β (Ford et al., 1981) . The fact that the estrogen produced by the conceptuses of these species acts locally to cause an abrupt transient increase in uterine blood flow suggests that estrogen may be acting nongenomically, at least initially, to promote this uterine vasculature response, just as it does in the ovariectomized cow given an intraarterial injection of estradiol-17β, as described above.
NONGENOMIC ACTIONS OF ESTROGEN

Nature of the Membrane-Associated Receptors
Evidence that estrogens could act to stimulate cell responses via an extranuclear mechanism was first advanced by the report of Pietras and Szego (1975) in the mid-1970s. However, because investigators of hormone action were at the time focused on characterizing nuclear steroid receptors and their function, the significance of this report was ignored. In a subsequent study, Pietras and Szego (1977) incubated estradiol-derivatized nylon monofilament fibers with cells of the endometrium, intestinal mucosa, and liver. Only endometrial and liver cells were found to adhere to the estrogenderivatized fibers, but not nontarget cells from the intestine. The results of this study provided direct proof that specific binding sites for estradiol were resident in the plasma membrane of target cells. Interest in the plasma membrane ER was piqued by the report of Razandi et al. (1999) . These investigators transfected cDNA for mouse ERα and ERβ into Chinese hamster ovary (CHO) cells. Expression of the cDNA for each receptor resulted in production of a single transcript that gave rise to both membrane and nuclear receptors. The membrane receptor number was only 3% as great as the nuclear receptor density. Treatment of cells with estradiol-17β stimulated a phosphoinositide cascade as well as activation of adenylate cyclase, suggesting that the receptors were coupled to Gα q and Gα s proteins. More importantly, exposure of the transfected cells to estradiol provoked an increase in extracellular-regulated kinase (ERK) activity within 10 min, which was considered to be the consequence of the nongenomic action of the steroid (Figure 1 ). The estrogen antagonist, Imperial Chemical Industries (ICI) 182,780, inhibited estradiol-17β and estradiol-17β-BSA conjugate activation of the mitogen-activated protein kinase (MAPK) components. Subsequently, Song et al. (2002) , using MCF-7 cells, provided evidence for a rapid direct physical association between ERα and Sarc homology collagen (Shc) adaptor protein upon stimulation of cells with estradiol-17β. Using a mutagenesis approach, the investigators demonstrated that Src homology (SH) 2 and phosphotyrosine binding domains of Shc and the AF-1 region of ERα are the interacting molecular sites of association. The presence of estradiol-17β rapidly in- Figure 1 . Nongenomic estrogen signaling pathways involving estrogen receptor α (ERα) and G-protein receptor (GPR30). Biochemical components of the pathways are as follows: E = estradiol-17β; P = phosphate; AC = adenylate cyclase; Gαβγ = heterotrimeric G-protein; cAMP = cyclic adenosine monophosphate; PKA = protein kinase A; MMP = a metalloproteinase; HB-EGF = heparin-bound epidermal growth factor; EGFR = epidermal growth factor receptor; ER = endoplasmic reticulum; Grb2 = growth factor receptor binding protein-2; Shc = Sarc homology collagen adaptor protein; SOS = son-of-sevenless, a guanine nucleotide exchange factor; Ras = a GTPase activated by GTP; Raf = a kinase also referred to as MAP kinase, kinase; MEK = a kinase also referred to as MAP kinase, kinase; ERK-1/-2 = extracellular regulated kinases also referred to as MAP kinase; Elk-1, c-fos, c-jun = transcription factors; TK = Tyr kinase; PI3K = phosphatidylinositol-3 kinase; PI4,5P 2 = phosphatidylinositol-4,5-bisphosphate; PI3,4,5P 3 = phosphatidyl inositol-3, 4,5-trisphosphate; Akt/PKB = protein kinase B; PLC = phospholipase C; and IP 3 = inositol-1,4,5-trisphosphate. Pathway interactions designated with a question mark are presently not well defined.
duced Shc phosphorylation, presumably by a Src protein family member, with the resultant formation of an Shc-growth factor receptor-binding protein-2-son-ofsevenless (SOS, a guanine nucleotide exchange factor) complex with a consequent phosphorylation of ERK-1/-2 and activation of the transcription factor Elk-1. Estradiol-17β rapidly induced (within 20 min) formation of membrane ruffles and pseudopodia in modified MCF-7 cells. The estradiol-induced morphological changes were prevented by the antiestrogen ICI 182,780. In a subsequent study, Song et al. (2004) examined how estradiol-17β interacts with ERα localized at the plasma membrane and the mechanisms by which Shc and IGF-I receptor (IGF-IR) mediate this process.
They were able to demonstrate that estradiol-17β rapidly induced formation of a ternary protein complex consisting of Shc, ERα, and IGF-IR. Knockdown of Shc with a specific small inhibitory RNA decreased the association of ERα and IGF-IR by 87%, suggesting that Shc is a crucial molecule in the formation of this ternary complex. Results of their experiments demonstrated that Shc and IGF-IR serve as key localized membrane elements that facilitate ERα-mediated rapid estrogen action.
The mechanism(s) by which nuclear steroid receptors could localize at the plasma membrane has been a puzzle. Recently, Pedram et al. (2007) provided an answer to this puzzle. These investigators identified a 9-AA motif to be highly conserved in the LBD of all sex steroid receptors; identical in mouse and human genes. This motif consists of F(X 6 ) LL, where X is any AA and L is Leu. In the case of ERα, 1 of the 6 X AA is Cys 447 , which, in the unoccupied receptor, undergoes palmitoylation by palmitoyl acyltransferase. Palmitoylation was shown to facilitate ERα translocation to the plasma membrane and association of the receptor with the membrane protein caveolin-1.
Mobilization of Ca 2+ may contribute to the observed nongenomic actions of estrogens. An early report by Morley et al. (1992) contained data indicating that exposure of pig granulosa cells to 10 −6 to 10 −10 M estradiol-17β caused an immediate 4-to 8-fold increase in intracellular Ca 2+ . This cellular response is specific of estrogens because various progestins and androgens were ineffective. The rapid estrogen-induced increase in intracellular Ca 2+ was not reduced by incubating the cells in Ca 2+ -free medium or by pretreating with Ca 2+ channel blockers. It appears then that the release of Ca 2+ is from intracellular stores triggered by inositol trisphosphate generated by an ER-induced hydrolysis of membrane phosphatidylinositol 4,5-bisphosphate.
There are some who believe the nongenomic action of estrogen, at least in some tissues, is mediated by a G protein-coupled receptor referred to as GPR30 (Figure 1) . This is a bizarre protein whose role as an ER and whose location within the cell are unsettled and controversial. Human SKBR3 breast cancer cells fail to express ERα and ERβ but do contain the GPR30 protein. Filardo et al. (2000) showed that exposure of these cells to estradiol-17β (1 nM) for 5 min resulted in phosphorylation of ERK-1/-2. Surprisingly, the estrogen antagonist, ICI 182,780 (1 M), was as effective as estradiol-17β in causing phosphorylation of ERK-1/-2. Further, in MDA-MB-231 cells, which express some ERβ but little GPR30 protein, there is no activation of ERK in response to either estradiol or the estrogen antagonist, suggesting that the classical ER are not mediators of estrogen action in this cell type. Proof of this was provided by results of an experiment in which a GPR30 cDNA was transfected into MDA-MB-231 cells, causing overexpression of the GPR30 protein. Exposure of these transfected cells to estradiol or ICI 182,780 caused phosphorylation of ERK-1/-2, whereas estradiol-17α and P 4 were ineffective. Filardo et al. (2000) provided evidence suggesting that estradiol signaling occurred via a Gβγ subunit-dependent, pertussis toxinsensitive pathway that ultimately results in transactivation of epidermal growth factor (EGF) receptor (EGFR) via the autocrine release of heparin-bound EGF. Binding of heparin-bound EGF to EGFR promotes receptor dimerization and autophosphorylation of Tyr residues within the cytoplasmic domain of the receptor. Specific recognition of these phosphotyrosines by the adapter proteins Grb-2, Shc, or both, and the guanine nucleotide exchange factor SOS forms the Grb-2-Shc-SOS adaptor protein complex, which links activated EGFR to MAPK via the monomeric GTPase, Ras. The Ras recruits Raf, which promotes cascade phosphorylation and activation of Mek-1 and its substrates ERK-1/-2. The response of human breast carcinoma cells to estradiol-17β in terms of phosphorylation of ERK-1/-2 is transient, rapidly returning to basal levels 30 to 60 min after initial exposure to estradiol. Filardo et al. (2002) hypothesized that estrogens also act via GPR30 to stimulate adenylate cyclase to inhibit the EGFR to MAPK pathway. Exposure of membranes from human SKBR3 breast cancer cells and MDA-MB-231 cells (that were forced to overexpress GPR30 protein) to estradiol and ICI 182,780 responded to treatment with an increase in adenylate cyclase activity as measured by production of cyclic adenosine monophosphate (cAMP). By contrast, estradiol and ICI 182,780 failed to cause stimulation of cAMP production by membranes isolated from MDA-MB-231 cells (which contain ERβ but neglible quantities of GPR30) or promote blockade of EGF-induced activation of ERK-1/-2. Evidence is presented suggesting that estrogen-induced suppression of ERK-1/-2 activity in cancer cells expressing GPR30 may be due to protein kinase A phosphorylation of Ser residues in Raf-1. Although the reports by Filardo et al. (2000 Filardo et al. ( , 2002 suggested that GPR30 was a resident of the plasma membrane, the more recent research of Revankar et al. (2005) indicated otherwise. To determine the cellular localization of the receptor, these latter investigators expressed GPR30 as a fusion protein with green fluorescent protein in COS-7 (monkey kidney fibroblast) cells. The receptor was expressed with the β 2 -adrenergic receptor, a G-protein-coupled receptor. Confocal fluorescent microscopy revealed that the β 2 -adrenergic receptor was localized to the plasma membrane, whereas GPR30-green fluorescent protein was localized in the endoplasmic reticulum and the Golgi apparatus. The same intracellular location for GPR30 was found for MCF-7, SKBR3, and MDA-MB-231 cells. Exposure of COS-7 cells bearing GPR30 to estradiol-17β causes a mobilization of intracellular Ca 2+ . Because GPR30 had been shown by Filardo et al. (2000 Filardo et al. ( , 2002 to activate the MAPK pathway via EGFR and mobilization of intracellular Ca 2+ is mediated by phospholipase C (PLC)-dependent inositol-1,4,5-trisphosphate production, an experiment was conducted to determine whether either of these pathways was involved in estrogen-stimulated Ca 2+ mobilization by ERα and GPR30. The GPR30-mediated Ca 2+ mobilization was completely blocked by an inhibitor of EGFR, but not by an inhibitor of PLC, whereas the ERα response was completely blocked by the PLC inhibitor, but not measurably so by the EGRF inhibitor. These data suggest that ERα-and GPR30-provoked Ca 2+ mobilization are mediated by distinctly different pathways.
Because of equivocal data regarding the cellular location of GPR30, Filardo et al. (2007) conducted a series of experiments to prove that GPR30 is present in the plasma membrane. For these experiments, HEK-29 cells transfected with a hemagglutin-epitope tag incorporated at the amino terminus of human GPR30 and the SKBR3 breast cancer cells were utilized. Using a variety of techniques, including confocal microscopy, western blotting of subcellular fractions, estrogen binding, and estradiol activation of G-protein in cell compartments, these investigators provided strong evidence that GPR30 is found in the plasma membrane. However, it should be noted that these cancer cells were, in some experiments, exposed to exceedingly high concentrations of estradiol.
Rapid Estrogen-Induced Responses by the Pituitary
Administration of estradiol-17β to ovariectomized ewes resulted in an almost immediate reduction in sys- 5 cells per well) were preincubated for 15 or 60 min in the presence of estradiol-17β (E 2 ), E 2 -BSA, or E 2 -peptide (PEP) and then exposed to 2 nM GnRH for 15 min. Mean ± SEM of LH released represent combined responses to all 3 forms of E 2 because no significant interactions between incubation time and dosage or between treatment and dosage were found. a-c Means with different letters differ (P < 0.01). Reproduced from Arreguin-Arevalo and Nett (2005) .
temic concentration of LH, followed in approximately 12 h by an ovulatory-type surge of the gonadotropin . The almost instantaneous response to estrogen suggested an inhibitory effect on the hypothalamus or hypophysis and precluded it being the result of the traditional effect of the steroid on gene expression. Recognizing that this response must be due to an extranuclear cellular site of action, Arreguin-Arevalo and Nett (2005) began to explore the mechanism by which estradiol-17β was able to evoke such a rapid response by the pituitary. Using a primary culture of ovine pituitary cells, these investigators showed that preincubation of cells for 15 min with estradiol-17β or estradiol-17β conjugated to BSA or a peptide (PEP) prevented GnRH-induced secretion of LH (Figure 2 ). This was a specific response to estradiol-17β because pretreatment of cells with P 4 , testosterone, hydrocortisone, or estradiol-17α failed to affect secretion of LH by themselves, and did not suppress GnRH-induced secretion of LH. Further, when pituitary cells were coincubated with these steroids plus estradiol-17β, they did not block the ability of estradiol-17β to inhibit GnRHinduced release of LH. Treatment of cells with tamoxifen, hydroxytamoxifen, or ICI 182,780 blocked inhibition by estradiol-17β (E 2 ) and the estradiol-17β conjugates (E 2 -BSA, E 2 -PEP). When cells were treated with selective ER agonists, the ERα-agonist (propylprazoletriol), but not the ERβ agonist (diarylpropionitrile), decreased the GnRH-induced secretion of LH. The fact that E 2 -BSA and E 2 -PEP mimicked the action of estradiol-17β suggests that this effect was mediated by an ER associated with the plasma membrane.
In a subsequent study, Arreguin-Arevalo and Nett (2006) infused ovariectomized ewes with estradiol-17β (50 g) for 4 h or with equimolar concentrations of E 2 -BSA or E 2 -PEP. Treatments with estradiol-17β, E 2 -BSA, and E 2 -PEP each induced an acute suppression of LH secretion in less than 20 min (Figures 3 and 4) . In contrast, estradiol-17β, but not E 2 -BSA and E 2 -PEP, induced the characteristic preovulatory-like surge of LH (at 10 to 12 h after primary treatment) and decreased secretion of FSH (at 4 h after primary treatment). These data led the investigators to conclude that the acute rapid inhibition of LH secretion induced by estradiol-17β in ovariectomized ewes was due to a nongenomic action of the steroid, and further, that the acute effect of estradiol-17β was mediated via a receptor associated with the plasma membrane.
Collectively, these investigators have demonstrated a nongenomic effect of estradiol-17β in altering a biological system by using both in vivo and in vitro approaches. Sensitivity of LH secretion in the ovariectomized ewe to the presence of estradiol-17β has proven to be one of the best models for showing that a nongenomic action of the steroid can provoke a documented biological response.
Rapid Estrogen Signaling in the Vascular System
As mentioned in an earlier section of this review, ovarian steroids have been shown to exert a local effect on the uterine arteries of domestic ruminants. In particular, the presence of estrogen was found to markedly increase arterial dilation and blood flow. Simoncini et al. (2000) reported that estrogen activated the phosphatidylinositol-3-kinase (PI3K)-Akt/protein kinase B pathway (Figure 1) , with consequent activation of endothelial nitric oxide synthase (eNOS). Using human vascular endothelial cells, these investigators demonstrated that ERα binds in a ligand-dependent manner to the p85α regulatory subunit of PI3K. Stimulation with estrogen increases ERα-associated PI3K activity. This kinase catalyzes the phosphorylation of phosphatidylinositol-4,5-bisphosphate to form phosphatidylinositol-3,4,5-trisphosphate. The phosphatidylinositol-3,4,5-trisphosphate associates with 3-phosphoinositide-dependent protein kinase-1, a protein kinase that phosphorylates Akt/protein kinase B and leads to enhanced activity of eNOS with a resultant increase in NO, which causes relaxation of vascular smooth muscle. Estrogen receptor β did not interact with p85α or recruit PI3K activity after estrogen stimulation. To determine whether estradiol-17β-stimulated eNOS activation was mediated by Akt, the investigators transiently transfected bovine aortic endothelial cells with adenoviruses containing constitutively active and dominant negative Akt mutants. Transfection of these endothelial cells with the constitutively active Akt resulted in a substantial increase in eNOS activity, whereas overexpression of the dominant negative Akt completely abolished estradiol-17β-stimulated eNOS activity. The short duration over which endothelial cells responded to estradiol-17β suggested that recruitment and activation of PI3K was by ligand-bound ERα but independent of gene transcription. In contrast to these observations, Chen et al. (2004) reported that estrogen-induced activation of eNOS in ovine uterine arterial endothelial cells (UAEC) occurred by a different pathway. According to these investigators, exposure of UAEC to estradiol increased eNOS activity and NO production within 2 min as a consequence of the estradiol binding to ERα in the plasma membrane. Exposure of UAEC to estradiol resulted in rapid phosphorylation of ERK-1/-2, which was maximal within 5 min after treatment of cells with the estrogen. Treatment of cells with the ER antagonist ICI 182,780 or PD98059, an inhibitor of the MAPK pathway, abolished estradiol-17β-induced phosphorylation of ERK-1/-2 and eNOS activity. However, exposure of UAEC to the PI3K inhibitor LY294004 failed to prevent estradiol-induced production of NO by these cells. The investigators concluded that rapid activation of eNOS to produce NO in ovine UAEC by estrogen is mediated, at least in part, through the MAPK pathway with activation of ERK, and not via activation of the PI3K pathway. The production of NO would result in rapid uterine vasodilation by estrogen, a phenomenon shown to occur in vivo.
NONGENOMIC ACTIONS OF PROGESTINS
Nature of the Membrane-Associated Receptors
Progesterone can activate several different nongenomic pathways dependent on the tissue or cell type and receptor type present in the system. A nongenomic action by the classical nPR has been implicated by several studies (Skinner et al., 1998; Bagowski et al., 2001; Vallejo et al., 2005; Boonyaratanakornkit et al., 2007; Evaul et al., 2007; Lange et al., 2007) . There is evidence that P 4 binding to a plasma membrane-localized or plasma membrane-associated nPR induces proliferation of murine endometrial stromal cells, via activation of MAPK, as a consequence of cross-talk with the classical ERβ (Vallejo et al., 2005) . At low levels of expression, nPR and ERβ form a complex, which activates both the MAPK pathway and the Akt pathway, and thereby stimulates the cell to progress through the mitotic cycle. Because both PR and ERβ are at low concentrations during the process of decidualization in the murine uterus, this may be an important mechanism in the rodent by which P 4 promotes the maintenance of pregnancy.
An SH3-interacting domain motif located in the Nterminus between AA residues 421 to 428 (near the AF-1 domain) was discovered by Boonyaratanakornkit et al. (2001) in both nPR-B and nPR-A. The SH3-interacting domains are polyproline sequence motifs characteristic of a class II consensus PEP for Src kinase-like SH3 domains. Polyproline sequences form a left-handed helix that recognizes the hydrophobic pocket of SH3 domain-containing proteins. In coimmunoprecipitation assays, the SH3 domain of nPR interacted with a wide variety of Src Tyr kinase family members, including Src Tyr kinase (Edwards et al., 2003) . The SH3 domain of Src recognizes the polyproline sequence, and this interaction participates in the activation of the Tyrkinase activity of Src. The Src Tyr kinase activates the MAPK cascade, which ultimately results in the phosphorylation or activation of several transcription factors, including c-fos and c-jun. Activation of the MAPK cascade rapidly induces transcription of cyclin proteins, which then cause the cell to enter into mitosis. Boonyaratanakornkit et al. (2007) , using breast cancer epithelial cells, determined that nPR-B was the isoform that preferentially activated Src and MAPK, and was important for inducing expression of the cyclin D1 gene. Mutated nPR-B (mutated in the proline-X-X-proline motif) was not able to induce cell-cycle progression or expression of cyclin D1. Although these responses seem to be genomic, because they occur within a few hours via activation of kinase cascades, they are considered to be nongenomic functions of the steroid receptor because the receptor itself does not interact with the DNA. These experiments were confirmed by the research of Faivre et al. (2005) , who observed an induction of phosphorylated ERK-1/-2 by treatment with progestin R5020 within 5 to 10 min, and activated MAPK was required for progestin to stimulate cyclin D1 and cdk 2 expression in MCF-7 and T47D breast cancer cells, both of which have high expression of nPR. Subsequent research by this group provided evidence for a biphasic response to P 4 treatment, with both P 4 -dependent upregulation of the EGF/Wnt-1 pathway in addition to the MAPK pathway needed to induce P 4 -mediated proliferation of progestin-responsive breast cancer cells (Faivre and Lange, 2007) .
The PI3K pathway may be induced by an isoform of nPR to mediate oocyte maturation and germinal vesicle breakdown in frogs (Xenopus laevis). The Xenopus PR is related to the mammalian PR-B isoform and is termed XPR-1. The XPR-1 has been observed localized to the plasma membrane of oocytes, and treatment with P 4 can activate PI3K within 30 min (Bagowski et al., 2001) . However, there is evidence that P 4 -mediated induction of the G-protein subunits βγ actually induce Xenopus oocyte maturation via Gβγ stimulation of adenylate cyclase (Guzmá n et al., 2005) . A recent study implicated classical steroid hormone receptors for both P 4 and testosterone in signaling through Gβγ in Xenopus by pharmacological methods, that is, by using the specific ligands R5020 and R881 (Evaul et al., 2007) . However, another study by Josefsberg et al. (2007) demonstrated that a recently discovered membrane PR β (mPRβ) ortholog, XmPRβ, mediates oocyte maturation in Xenopus. These researchers used microinjection of a neutralizing antibody to XmPRβ into the oocyte and could block the P 4 -induced maturation. There was also an induction of MAPK within 10 min after transfected (XmPRβ) CHO cells were exposed to 30 nM P 4 . The effect of XmPRβ on Gβγ signaling was not investigated. Thus, the exact protein that mediates rapid P 4 -initiated events in Xenopus oocytes remains to be determined. It may be that all of the above signaling cascades are necessary, or this may represent a redundancy in this important system.
A novel membrane-associated PR has been identified that is functionally and structurally distinct from genomic nPR: a G-protein-coupled receptor first characterized in spotted seatrout ovaries (Thomas et al., 2002 ).
In the spotted seatrout, a progestin (17,20β,21-trihydroxy-4-pregnen-3-one) rapidly mediates the induction of oocyte maturation (Thomas et al., 2002) . This action occurs at the cell surface, is not blocked by inhibiting transcription, and is induced rapidly within a few minutes of progestin administration, suggesting these actions are not mediated by an nPR. Zhu et al. (2003b) described this protein: a 352-AA protein with a molecular weight of 40 kDa with 7 transmembrane domains characteristic of a G-protein-coupled receptor. Homologous genes for this mPR were found to exist in humans, mice, and swine via a BLAST search (Zhu et al., 2003a) . Similar proteins have been identified by other researchers in human myometrium (Fernandes et al., 2005) and in ovine hypothalamus, pituitary, uterus, ovary, and corpus luteum (Ashley et al., 2006) . There are some conflicting data that suggest these proteins cannot mediate plasma membrane events (Ashley et al., 2006; Krietsch et al., 2006) . Novel mPR isoforms have been shown to decrease cAMP levels in Atlantic croaker (Micropogonias undulates) oocytes, and germinal vesicle breakdown (GVBD; a marker of oocyte maturation) was blocked by inhibition of the PI3K/Akt pathway (Pace and Thomas, 2005) . Although MAPK activation was observed in croaker oocytes, blockage of MAPK activation did not inhibit GVBD, suggesting that signaling via PI3K/Akt is the primary mechanism by which GVBD occurs in response to P 4 in croaker oocytes.
Signaling through the ovine mPR in transfected CHO cells demonstrated rapid (within 1 min) increases in intracellular calcium (Ashley et al., 2006) . When cellular localization was studied, the ovine mPR localized to the endoplasmic reticulum. Because the increase in intracellular calcium was via liberation of cellular calcium stores, the mPR could function in this manner to stimulate rapid steroid responses. It is notable, however, that some researchers claim the mPR is localized to the plasma membrane and mediates plasma membrane-associated responses (Thomas, 2003; Zhu et al., 2003b; Pace and Thomas, 2005) . Other studies in transfected cells in addition to that by Ashley et al. (2006) have visualized the mPR localized to either the endoplasmic reticulum (human mPRα, β, and γ; Krietsch et al., 2006) or to an intracellular tubular network (human mPRα isoform only; Fernandes et al., 2005) . There may be species differences in the cellular localization (and signaling pathways) of these proteins. Interestingly, Krietsch et al. (2006) duplicated the materials and methods of Zhu et al. (2003b) and were unable to stimulate either cAMP production or MAPK activity with transfected human mPR and both pufferfish and spotted seatrout mPR sequences (seatrout mPR sequence was provided by Zhu et al. 2003b ). Because the seatrout mPR sequence was amplified by PCR before inserting into the vector, some small mutations may have been induced that affected the protein sequence of the transfected seatrout mPR.
Membrane P 4 -binding proteins have been identified in spermatozoa, bovine follicular and luteal cell membranes, and murine granulosa cells by using the c-terminal PR antibody c-262 (Peluso et al., 2001; Bramley et al., 2002; Luconi et al., 2002) . There is some debate regarding whether the P 4 -binding protein in spermatozoa could be nPRC (Luconi et al., 2002) . Peluso et al. (2001 Peluso et al. ( , 2003 later characterized the P 4 -binding protein in the membranes of murine granulosa cells. Progesterone prevents these cells from entering into an apoptotic pathway. Because these cells in the rat ovary do not express nPR before the preovulatory surge of gonadotropin, it is unlikely the binding protein is nPR. Peluso et al. (2004) cloned this P 4 -binding protein and found it to consist of 407 AA, similar to a homolog expressed in the mouse lung. After a domain analysis, this protein was termed plasminogen activator inhibitor mRNA binding protein-1 (PAIRBP-1) for its homology to other proteins (Peluso et al., 2006) . The analysis provided no evidence of a transmembrane domain, but did identify several hyaluronic acid binding sites. Further investigation of PAIRBP-1 by Peluso et al. (2006) led to the identification of a membrane-bound partner, PR membrane component-1 (PGRMC-1), that is required for PAIRBP-1 to exert the effects mediated by P 4 on these cells. The PGRMC-1 is a relatively small protein (28 kDa) and possesses a short N-terminal extracellular domain, a single transmembrane domain, and a cytoplasmic domain that contains several potential SH2 and SH3 domains. The PGRMC-1 protein is homologous to the IL-6 receptor, a member of a growth factor receptor superfamily that includes the cytokines, growth hormone, and prolactin. Progesterone receptor membrane component-1 has been observed as a dimer (56 kDa), but can form aggregates up to 200 kDa. When spontaneously immortalized granulosa cells are treated with an antibody that blocks the N-terminal extracellular domain, treatment with P 4 will not result in a decrease in the total number of apoptotic spontaneously immortalized granulosa cells (Peluso et al., 2006) .
Rapid Progestin Inhibition of the Hypothalamus
The first evidence of a nongenomic action of P 4 in the brain was reported in the 1940s by Hans Selye (1942) , who observed an anesthetic effect almost immediately after administration of a bolus of P 4 to rats. Researchers in 1959 later observed depressed electroencephalogram activity in female rabbits following the postcoitis rise in P 4 (Sawyer and Kawakami, 1959) .
Later research demonstrated in the hypothalamus that allopregnanolone (3α,5α-tetrahydroprogesterone) enhances the inhibitory effect of gamma-aminobutyric acid (GABA) on GABA type A (GABA A ) receptor-expressing neurons, possibly through P 4 secreted from neighboring glial cells (Rønnekleiv and Kelly, 2005) .
Evidence suggests that P 4 is rapidly metabolized in the brain, and the metabolites (i.e., allopregnanolone) actually mediate the rapid effects of P 4 in the brain.
However, there is also evidence for a direct effect of P 4 in the hypothalamus. Hamsters primed for 2 h with P 4 , upon receiving a bolus injection of P 4 (or P 4 conjugated to BSA) directly into the midbrain ventral tegmental area rapidly exhibit lordosis behavior (within 10 min; DeBold and Frye, 1994) . Progesterone administered concurrently with estradiol-17β in the hypothalamus/ preoptic area of the ewe can rapidly inhibit the estradiol-induced preovulatory surge of GnRH and LH (Richter et al., 2005) . These actions are presumed to be mediated by the nPR, because of the observations of Skinner et al. (1998) that, upon pretreatment with RU 486 (an nPR antagonist), P 4 can no longer inhibit estradiolinduced GnRH secretion. In ovariectomized estradiolprimed ewes, removal of a P 4 implant will rapidly increase the frequency of pulsatile GnRH release (within 175 min), and these effects are seen only in estradiolprimed females. Further investigation by Richter et al. (2005) revealed that the inhibition by P 4 was most likely at the level of estradiol signaling, and not at the level of GnRH release, because treatment with P 4 after the onset of the estradiol-induced surge did not inhibit GnRH release.
Expression of OT neurons in the supraoptic nucleus and the paraventicular nucleus of the hypothalamus are under control of GABA via GABA A receptors in these neurons (Brussaard et al., 2000) . Treatment of OT neurons with GABA decreases the rate of firing, seen as an increase in the amount of time required to resensitize Cl − channels. During late pregnancy in female rats, metabolites of P 4 have been shown to inhibit firing of OT neurons by preventing protein kinase C-induced modulation of GABA A receptors. During parturition, GABA A receptors are less sensitive to P 4 metabolites, and counteraction of protein kinase C no longer occurs. This is accompanied by an increase in firing activity of OT neurons at the time of parturition (Brussaard et al., 2000) .
In some reports, the short time between exposure to P 4 and the detected hypothalamic response suggest that the effects of P 4 may be mediated by membrane-associated steroid binding proteins. Results of research involving the use of PR antagonists (see Skinner et al., 1998) revealed that the membrane-associated binding protein may in fact be the nPR. The true identity of the hypothalamic membrane progestin binding protein(s) remains to be determined.
Rapid Progestin Inhibition of Uterine OTR Activation
In studies of the bovine endometrium, a relatively high molar concentration of P 4 (10 −5 M) was able to inhibit the OT-stimulated release of PGF 2α from dissociated endometrial epithelial cells in the presence of actinomycin D (which blocks RNA synthesis from DNA; Bogacki et al., 2002) . In these cells, P 4 blocked both the binding of OT to its receptor and OT-stimulated Ca 2+ increase. Various steroids were then investigated (progestins and testosterone at 10 −5 M; Duras et al., 2005) for their ability to inhibit OT signaling. All steroids investigated inhibited OT-induced PGF 2α secretion and intracellular Ca 2+ response. The observed cellular responses were attributed to a nongenomic action of steroids. But the authors did acknowledge the possibility that such responses might actually represent artificial, nonspecific effects of the steroids because of a long (4-h) incubation period and a comparatively high concentration of steroids utilized.
This premise was tested by Burger et al. (1999) , who investigated the effects of progestins at a range of doses between 10 to 200 M on human OTR transfected into various cell lines. These researchers reported that their data demonstrated that the effects of P 4 on OT binding and OTR function were nonspecific steroid effects, that is, a steroid overloading of the plasma membrane, which then interferes with the ability of the OTR to interact with signaling proteins. Wenz and Barrantes (2003) , using artificial membrane bilayers, tested the effects of various steroids, including P 4 , on the integrity of lipid domains. Their data indicated that the lower the hydrophobicity of the steroid (hydrophobicity determined by the group bound to carbon 17), the more lipid domain-disrupting activity the steroid displayed at higher molar concentrations. Progesterone and all naturally occurring metabolites of P 4 that possess low hydrophobicity groups attached to carbon 17 demonstrated domain-disrupting activity in the artificial lipid domains, but only at high molar concentrations (10 M P 4 ).
In ovine endometrial plasma membranes, a lower, more physiological concentration of P 4 (16 nM) can specifically inhibit the binding of OT to the OTR ( Figure  5 ; Dunlap and Stormshak, 2004) . The fact that RU 486 (antagonist) can block the inhibiting effect of P 4 on binding of OT suggests the possibility that membrane-localized nPR may somehow be associated with the OTR. Inhibition of OT binding by P 4 may reflect an induced allosteric alteration in the structural conformation of the OTR monomer or dimer, which is directly or indirectly relieved or prevented by an antagonist to the nPR such as RU 486. Similarly, inhibition of OT binding by P 4 and progestins at physiological levels (below 1 M) of P 4 has been reported from studies of the murine and the human OTR (Grazzini et al., 1998) . Specific and saturable membrane binding of progestins has been characterized in the ovine endometrium, and the binding sites for OT and progestin appear to be closely associated in this tissue (Dunlap and Stormshak, 2004) . In the ewe, the inhibition of OT binding to membrane preparations by low levels of P 4 (2 to 16 nM) is dose dependent (Figure 6 ; Bishop and Stormshak, 2006) . As stated above, there is evidence suggesting that P 4 inhibits OT binding either by competing with OT for its receptor site or by binding to a closely associated protein that alters OTR conformation. Bishop and Stormshak (2006) demonstrated that preexposure of ovine endometrial explants to P 4 (8 nM) rapidly inhibited OT-induced a,b Means ± SEM with different letters differ (P < 0.05). Reproduced from Dunlap and Stormshak (2004) .
phosphoinositide hydrolysis (within 30 min; Figure 7 ) and OT-induced PGF 2α production (within 2 h). Thus, there is evidence in the ruminant endometrium for a physiologically relevant nongenomic action of P 4 to interfere with the ability of OT to signal through the OTR. The data generated from the bovine model (Bogacki et al., 2002; Duras et al., 2005) may represent an artificial, in vitro effect of steroid as suggested by Burger et al. (1999) . However, the effects of lower concentrations of P 4 in the ovine endometrium (Dunlap and Stormshak, 2004; Bishop and Stormshak, 2006) may represent a 3 H]-myo-inositol into inositol-1,4,5-trisphosphate (IP 3 ) in ovine endometrial explants after incubation in the presence of vehicle, 2.5 ng/mL progesterone (P 4 ), 100 nM oxytocin (OT), or P 4 + OT. a-c Means ± SEM with different letters differ (P < 0.05). Reproduced from Bishop and Stormshak (2006) . Copyright 2006, The Endocrine Society. more specific effect because progestins display lipiddomain effects at high molar concentrations only (Wenz and Barrantes, 2003) . The ovine endometrium also displays specific and saturable binding to P 4 by the radioligand binding assay (Dunlap and Stormshak, 2004) . The ovine mPR has been observed in the uterus of the ewe (Ashley et al., 2006) , but whether this protein is involved in the inhibition of the OTR remains to be investigated. The fact that this protein appears to be localized to the endoplasmic reticulum makes a direct protein-protein interaction between the mPR and the OTR unlikely, but the mPR may mediate other downstream signaling events that interfere with OTR function. Rae et al. (1998a) observed P 4 binding in the membranes of bovine granulosa, theca, and luteal cells. Binding of the steroid to membrane fractions of luteal cells (but not granulosa and theca cells) is dependent on digitonin (a molecule similar to cholesterol used as a detergent), which functions as a sterol-binding agent and disrupts caveolae and lipid rafts. Several progestins and related steroids were investigated for their ability to displace binding of P 4 to cell membranes; RU 486 (nPR antagonist) had no effect on binding of P 4 , and both 5α-hydroxyprogesterone and 5β-hydroxyprogesterone displayed 10-to 20-fold lower affinity for the binding site (ruling out a GABA A receptor involvement; Rae et al., 1998b) . Other steroids investigated did not display high-affinity binding. The authors suggested that these mPR are hidden in the luteal cell membranes, and treatment with digitonin depletes the naturally occurring membrane cholesterol and allows binding sites for P 4 to be "unmasked" (Rae et al., 1998a; Menzies et al., 1999) . It is unknown which mPR (the G-protein-coupled receptor or the complex identified by Peluso et al., 2006) is specifically binding P 4 in bovine steroidogenic cells, but because RU 486 does not compete for binding of P 4 in luteal cells, the genomic nPR may not be involved. Bramley et al. (2002) suggest that the evidence points to a complex of proteins, similar to the PAIRBP-1/PGRMC-1 complex in the rodent. Treatment of bovine luteal cells with P 4 decreases apoptosis (Rueda et al., 2000) , but unlike murine granulosa cells, bovine granulosa cells do express the nPR. Currently, the specific protein(s) mediating membrane-initiated P 4 signaling in the bovine corpus luteum have not been elucidated.
Other Nongenomic Progestin Signaling
Treatment of diestrus-II rat uteri with P 4 (40 g/mL) and metabolites of P 4 (3β-hydroxy-5β-pregnan-20-one, 5β-pregnan-3,20-dione, and 3α-hydroxy-5α-pregnan-20-one) will inhibit uterine contractions within 2 min (Putnam et al.,1991) . The effects of P 4 only are blocked by treatment with RU 486, but a GABA A receptor antagonist (picrotoxin) will block the inhibitory effects of the metabolites. Picrotoxin does not affect the ability of P 4 to inhibit contractions. This suggests that during gestation in the rat, P 4 metabolites may act through a GABA A receptor system to inhibit uterine contractions (Putnam et al., 1991) .
It has been reported that P 4 may bind to an mPR in bovine T lymphocytes to prevent proliferation of stimulated cells via inhibition of the α subunit of the IL-2 receptor (Cannon and Pate, 2004) . More recently, Ndiaye et al. (2007) demonstrated the presence of mPRα, β, and γ and PCRMC-1 but not nPR, in T lymphocytes.
Spermatozoa respond to stimulation by P 4 and they lack a transcriptionally active nucleus. These cells lack both nPR-A and nPR-B, but P 4 treatment can stimulate calcium influx, Tyr phosphorylation of proteins, efflux of chloride, and increases in cAMP (Luconi et al., 2002) . In the travels of spermatozoa to the oocyte, they do come into contact with increased concentrations of P 4 within the cumulus oophorus (1 to 10 g/mL of P 4 has been measured in cells surrounding human oocytes; Luconi et al., 2002) . Progesterone stimulates capacitation of human spermatozoa and induces the acrosome reaction in caprine spermatozoa (Somanath et al., 2000) . Possible candidates for a PR have been identified by using the c-terminal PR antibody c-262, as mentioned before (Luconi et al., 2002) , and the 56-to 57-kDa protein may be similar to the one identified by Peluso et al. (2001) as being present in the ovary. However, characterization of this protein has yet to be performed. There is some discussion about whether this putative PR could be another isoform of the genomic PR, the PR-C form (Luconi et al., 2002) .
BIOLOGICAL SIGNIFICANCE
Responses to the genomic action of steroids in vivo are sometimes so profound they can be observed visually or, at the very least, be readily quantified by using appropriate laboratory techniques. On the other hand, responses to the nongenomic effects of steroids in animals that can actually be measured have been few, and consequently skepticism exists regarding the biological significance of this mode of steroid action. Perhaps the best example of an in vivo nongenomic effect of a steroid is the ability of exogenous estradiol-17β to cause a rapid reduction in the secretion of LH in ovariectomized ewes, as discussed previously. Similarly, estradiol-17β has been shown to promote rapid increases in uterine blood flow at estrus in the cow and ewe. This rapid response is attributed to the ability of estradiol to stimulate eNOS in endothelial cells to produce the vasodilator NO. In vivo responses to the nongenomic effects of P 4 are less pronounced than those for estrogen. Nevertheless, experimental evidence suggests that P 4 can interfere with the binding of OT to its receptor in the uterus of the cow and ewe.
Responses to the nongenomic action of steroids may also be so subtle as to be nondetectable. As an example, there is evidence that steroids may act nongenomically to sensitize intracellular systems for the purpose of enhancing their subsequent genomic transcriptional efficiency. This possibility is supported by the data of Vasudevan et al. (2001) , who subjected SK-NE-BE(2)C neuroblastoma cells transfected with human (h) ERα to a 2-pulse exposure of estrogen. Cells were first exposed for 20 min to 10 −9 M estradiol-17β-BSA, followed after 4 h by exposure to a second pulse of 10 −9 M estradiol-17β. This treatment sequence significantly increased transcriptional expression of hERα as compared with controls or cells having been exposed to only estradiol-17β (E 2 ). A reverse-pulse sequence in which cells were first exposed to E 2 and then E 2 -BSA did not potentiate transcription, demonstrating that E 2 -initiated membrane events are essential for later transcriptional effects. Of course, it is possible that the apparent beneficial nongenomic effect of estradiol-17β is attributed to free E 2 having been leached off the E 2 -BSA, and thus entering the cell to directly initiate the transcription processes 4 h prior to exposure of cells to a larger concentration of E 2 . The result of this latter scenario could be an enhanced transcription of the hERα.
In conclusion, the literature is replete with a preponderance of reports describing the nongenomic actions of estrogens and progestins in transfected or cancer cells. However, although these studies have been instrumental in promoting interest in the field, there is a need for further research to document the importance of the nongenomic action of steroids to the biology of the living animal.
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